Loading...
XSHE
002437
Market cap1.01bUSD
Dec 05, Last price  
3.24CNY
1D
0.62%
1Q
-6.63%
Jan 2017
-60.30%
IPO
12.93%
Name

HARBIN GLORIA PHARMACEUTICALS Co Ltd

Chart & Performance

D1W1MN
XSHE:002437 chart
P/E
30.56
P/S
2.91
EPS
0.11
Div Yield, %
Shrs. gr., 5y
0.57%
Rev. gr., 5y
-13.55%
Revenues
2.44b
-7.06%
164,113,010275,610,229429,928,954575,448,365546,364,548711,030,3031,307,886,2461,905,823,9912,681,225,3072,983,728,1363,041,883,4535,481,339,8285,053,859,8943,054,949,2663,145,311,7033,107,945,1602,626,039,3062,440,732,030
Net income
233m
+93.43%
74,755,721105,950,873130,235,113154,713,039116,848,259164,769,964226,737,497443,770,001664,808,612716,648,314309,675,737125,893,6340400,049,12245,042,0240120,334,186232,759,457
CFO
411m
+49.88%
52,260,50757,809,411170,815,046112,592,505128,606,944205,889,113453,020,477674,036,849702,047,2041,040,487,154651,795,3251,162,761,434610,365,81712,763,852274,181,021261,615,607274,175,284410,935,803
Dividend
Jun 28, 20190.012 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Harbin Gloria Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products primarily in the People's Republic of China. It offers cardiac cerebrovascular medication, skeletal muscle system, vitamins and minerals, urinary system medication, antitumor medication, endocrine medicine, anti-infective drugs, respiratory medication, antihistamine, peptic, and other products. Harbin Gloria Pharmaceuticals Co., Ltd. was founded in 2000 and is based in Harbin, the People's Republic of China.
IPO date
Jun 23, 2010
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT